UC Davis Scientists Launch VESSEL Platform to Decode Extracellular Vesicles for Next-Generation Therapeutics

Biomedical engineers at the University of California, Davis have unveiled a groundbreaking research platform that could transform the future of precision medicine, cancer treatment, and neurological therapies. The new system, called VESSEL (Vesicle Engineering Systems using Synthetic Expression and Loading), allows scientists to define protein function in extracellular vesicles (EVs) for the first time.

Published in ACS Nano, the research introduces a powerful method to better understand how EV surface proteins influence cell communication — opening the door to engineered EV-based therapeutics.

What Are Extracellular Vesicles (EVs)?

Extracellular vesicles (EVs) are microscopic, membrane-bound particles released by cells. Often described as the body’s “biological messaging system,” EVs transport:

• Nucleic acids
• Proteins
• Lipids

These tiny biological bubbles play a critical role in:

• Tissue repair
• Neuroprotection
• Immune regulation
• Intercellular communication
• Cancer progression and suppression

Because EVs naturally carry biological signals between cells, scientists have long recognized their therapeutic potential. However, one key mystery has remained unresolved: What determines the specific function of an EV?

The Missing Link: EV Surface Proteins

EV surface proteins are believed to dictate how vesicles interact with recipient cells. Yet until now, researchers struggled to isolate and analyze the role of individual proteins.

As Professor Aijun Wang explains, EV-mediated communication controls numerous physiological and pathological processes. While EVs show therapeutic promise, defining the function of their surface proteins has been like trying to interpret words without understanding their meaning.

In other words, scientists could see the proteins — but they couldn’t decode their biological significance.

That’s where VESSEL comes in.

Introducing VESSEL: A Breakthrough in EV Research

Developed through collaboration between the Tan Lab and Wang Lab at the University of California, Davis, VESSEL is a highly adaptable platform designed to isolate and study individual EV surface proteins.

The system works by creating synthetic vesicles that contain only one specific EV surface protein at a time. This allows researchers to:

• Probe protein function in isolation
• Identify how specific proteins influence cell uptake
• Build a functional “biological dictionary” of EV components

According to Professor Cheemeng Tan, the platform is intentionally designed to be generalizable. If a laboratory already uses cell-free protein expression systems — common in both academia and industry — it can adopt VESSEL with relative ease.

This scalability makes the system especially promising for widespread research adoption.

The Role of Cell-Free Protein Systems

One of VESSEL’s most innovative features is its use of cell-free systems to produce synthetic EV surface proteins.

Cell-free systems act as biological factories, enabling rapid and efficient protein production without relying on living cells. These systems are widely used in biotechnology research and pharmaceutical development.

By leveraging this approach, VESSEL offers:

• Faster experimentation
• Controlled protein expression
• Greater flexibility in protein design
• Scalable therapeutic applications

This represents a significant advancement in extracellular vesicle engineering and synthetic biology.

Key Discovery: CADM1 Protein and Vesicle Uptake

In the study, Tanner Henson, a Ph.D. student in biomedical engineering and first author of the paper, applied VESSEL to profile EVs derived from mesenchymal stem cells — known for their regenerative and anti-inflammatory properties.

One of the most notable findings was the identification of CADM1, a protein not previously referenced in EV-related medical literature.

The research suggests CADM1 may play a key role in facilitating vesicle uptake by cells. If validated in further studies, this discovery could significantly influence how engineered EVs are designed for targeted therapies.

Understanding which proteins control cell targeting and uptake is crucial for developing precision therapeutics.

Why This Matters for Cancer and Neurological Disorders

The implications of VESSEL extend far beyond academic research.

Engineered EVs are increasingly being explored as drug delivery vehicles because they:

• Are naturally biocompatible
• Can cross biological barriers
• Minimize immune rejection
• Deliver cargo directly to target cells

With VESSEL enabling precise functional mapping of EV surface proteins, researchers may soon be able to design customized vesicles for:

• Cancer immunotherapy
• Neurodegenerative diseases
• Stroke recovery
• Autoimmune disorders
• Regenerative medicine

As Henson notes, the long-term vision is translational — moving from laboratory discovery to real-world clinical application, particularly in neurological disease treatment.

Funding and Future Outlook

The research received support from major U.S. health research agencies, including:

• The National Institute of Neurological Disorders and Stroke
• The National Institute of General Medical Sciences
• The National Institute of Biomedical Imaging and Bioengineering

This backing underscores the high potential impact of VESSEL in advancing biomedical engineering and precision medicine.

A New Era in Extracellular Vesicle Engineering

The development of VESSEL represents a pivotal moment in EV research. By enabling scientists to define protein function within extracellular vesicles for the first time, the platform transforms EVs from mysterious biological messengers into programmable therapeutic tools.

Much like building with LEGO blocks, researchers may soon assemble vesicles with specific proteins to achieve precise medical outcomes.

As extracellular vesicle therapy continues to gain traction in cancer research, regenerative medicine, and neurological treatment, platforms like VESSEL could play a central role in shaping the next generation of personalized therapeutics.

The future of medicine may very well travel inside a tiny biological bubble — now, finally, decoded.